|
|
Article: InNexus Biotechnology Welcomes Dr. Ronald Levy, Stanford University School of Medicine Oncology Division Chief, to Scientific Advisory Board.
- Article from:
- Business Wire
- Article date:
- February 11, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BRITISH COLUMBIA, Canada -- InNexus Biotechnology Inc. (OTCBB:IXSBF) (TSX VENTURE:IXS) (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL[TM]) technology, welcomes Dr. Ronald Levy to its Scientific Advisory Board, effective immediately.
Dr. Levy has had strong ties with Stanford University since receiving his MD from the institution in 1968 and currently serves as the Stanford University School of Medicine Chief of the Division of Oncology, a position he has enjoyed since 1993. Among his many honors and awards, Dr. Levy has been the recipient of the Damashek ...